A study examining the relation between rituximab infusion and hospitalization as a result of COVID-19 for patients with multiple sclerosis (MS) found that the 2 were not related, contradicting past research.
Among patients with multiple sclerosis (MS) receiving rituximab therapy, the risk of COVID-19-related hospitalization was not influenced by the timing or cumulative dose of rituximab (Rituxan), according to a recent study published in JAMA Network Open.
Past research has shown that rituximab treatment is associated with more severe COVID-19 symptoms in people with MS. However, this finding was based on a small number of events, suggesting that more research is needed to confirm whether rituximab has a relationship to severe COVID-19.
The investigators conducted a nationwide nested case-control study using prospective data from the COMBAT-MS observational drug trial cohort. The participants were people with MS who were receiving ongoing treatment with rituximab when they experienced COVID-19 onset between March 1, 2020 and April 30, 2021.
The odds of COVID-19 hospitalization were examined in relation to the time between the most recent rituximab infusion and the COVID-19 onset and the total cumulative lifetime dose of rituximab received using logistic regression. Logistic regression models were adjusted for age, sex, and disability scores prior to the COVID-19 pandemic as determined by the Expanded Disability Status Scale. Data on race and ethnicity was omitted and the sensitivity analysis only included only persons with polymerase chain reaction-confirmed COVID-19 infection.
Among the 3391 Swedish people were enrolled in the COMBAT-MS cohort, 326 (9.6%) were confirmed to have COVID-19 during the study period. Of those diagnosed with COVID-19, 172 (52.8%) received rituximab before onset of COVID-19 and 26 (15.2%) required hospitalization, of whom 5 were admitted to an intensive care unit and 3 required ventilation. No deaths occurred among the cohort.
Age, disease duration, and disease course did not influence hospitalization among the patients with mild cases of COVID-19. The median time between the most recent rituximab infusion and COVID-19 onset was 6.1 months among patients with mild COVID-19 and 4.6 months among those who were hospitalized for COVID-19 (P = .16). People with mild COVID-19 had a median cumulative lifetime rituximab dose of 3.5 g compared with 2.2 g for patients who were hospitalized.
Time from the most recent rituximab dose was not associated with the odds of needing to be hospitalized (adjusted OR [aOR], 0.99; 95% CI, 0.92-1.04). Additionally, cumulative lifetime dose of rituximab was not associated with hospitalization odds (aOR, 1.08; 95% CI, 0.83-1.38).
After categorizing rituximab timing, patients with an infusion less than 4 months prior to COVID-19 onset were more likely to be hospitalized compared with patients whose last infusion was greater than 8 months prior to COVID-19 onset. However, this association was not significant after adjusting for age, sex, and disability score.
The investigators listed a potential ascertainment bias and missing information regarding risk factors for COVID-19 severity, including smoking and comorbidities, as study limitations.
“In conclusion, large data sets with data capture that is less prone to surveillance bias and with access to a broader range of confounding factors are necessary to settle the question of whether continued use of rituximab during the COVID-19 pandemic increased the risk of severe COVID-19 infection,” wrote the investigators.
Reference
McKay KA, Piehl F, Englund S, et al. Rituximab infusion timing, cumulative dose, and hospitalization for COVID-19 in persons with multiple sclerosis in Sweden. JAMA Netw Open. December 1, 2021;4(12):e2136697. doi:10.1001/jamanetworkopen.2021.36697
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More